In fact, Galasko et al. (2012) conducted a double-blind, placebo-controlled clinical trial to evaluate what antioxidant supplementation affected the levels of AD’s histopathological marks, such as Aβ peptide and tau protein [38]. This evidence concerns the gene MAPT and Alzheimer disease.